Aspergillosis

Apr 23, 2018

SCYNEXIS Data Presentations at ECCMID 2018 Show SCY-078 Potent and Synergistic Antifungal Activity Against Aspergillus and Pneumocystis

Apr 10, 2018

SCYNEXIS to Present SCY-078 Data at the 28th European Congress of Clinical Microbiology and Infectious Disease (ECCMID)

Mar 19, 2018

Amplyx Pharmaceuticals Receives Fourth "Qualified Infectious Disease Product" (QIDP) Designation from the FDA for APX001

Feb 12, 2018

Pulmatrix Announces First Subject Dosed in Phase 1 Clinical Trial of Pulmazole - an Inhaled Dry-Powder iSPERSE(TM) Formulation of Itraconazole

Feb 01, 2018

SCYNEXIS Presents New In Vivo Data Highlighting the Potential of SCY-078 Used in Combination for the Treatment of Aspergillus Infections at AAA 2018

Jan 24, 2018

Pulmatrix Will Present Pulmazole Preclinical Data at the 8th Advances Against Aspergillosis Conference to be Held February 1 - 3, 2018

Jan 04, 2018

SCYNEXIS Provides Corporate and SCY-078 Pipeline Update

Oct 03, 2017

Pulmatrix Antifungal Drug Candidate Receives a Second "Qualified Infectious Disease Product" (QIDP) Designation from the FDA

May 30, 2017

Aspergillosis Pipeline Market Global Analysis and Therapeutics Development H1 2017 Report now Available at RnRMarketResearch.com